|Bid||48.40 x 900|
|Ask||50.20 x 1300|
|Day's Range||43.49 - 50.20|
|52 Week Range||38.85 - 202.73|
|Beta (5Y Monthly)||2.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The last three months have been tough on Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders, who have seen the...
Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?